

Page 9, line 28, please delete "a".

Page 9, line 33, please change "valencey" to --valency--.

Immediately after page 36 and before the first page of claims (page 37), if appropriate, please insert the enclosed pages identified as --Sequence Listing--.

IN THE CLAIMS:

Please add the following claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents:

--38. A vaccine for eliciting an immunological response against porcine parvovirus and porcine circovirus comprising at least one porcine parvovirus antigen and at least one porcine circovirus antigen, and a veterinarily acceptable vehicle or excipient.

39. A vaccine of claim 38 wherein the porcine circovirus antigen comprises at least one porcine circovirus type II antigen.

40. A vaccine of claim 38 wherein the porcine parvovirus antigen is selected from the group consisting of an attenuated porcine parvovirus, an inactivated porcine parvovirus, a subunit of porcine parvovirus, and a vector that contains and expresses *in vivo* a nucleic acid molecule encoding the porcine parvovirus antigen; and the porcine circovirus antigen is selected from the group consisting of an attenuated porcine circovirus, an inactivated porcine circovirus, a subunit of porcine circovirus, and a vector that contains and expresses *in vivo* a nucleic acid molecule encoding the porcine circovirus antigen.

41. A vaccine of claim 40 wherein the vector that contains and expresses *in vivo* a nucleic acid molecule encoding the porcine parvovirus antigen is selected from the group consisting of a DNA plasmid, a linear DNA molecule, and a recombinant virus; and, the vector that contains and expresses *in vivo* a nucleic acid molecule encoding the porcine circovirus antigen is selected from the group consisting of a DNA plasmid, a linear DNA molecule, and a recombinant virus

42. A vaccine of claim 39 wherein the porcine circovirus type II antigen is at least one antigen of a porcine circovirus type II deposited at the ECACC selected from group consisting of: porcine circovirus type II accession No. V97100219, porcine circovirus type II

accession No. V97100218, porcine circovirus type II accession No. V97100217, porcine circovirus type II accession No. V98011608, and porcine circovirus type II accession No. V98011609.

43. A vaccine of claim 38 wherein the vaccine further comprises an additional antigen of another porcine pathogen.

44. A vaccine of claim 43 wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of *Mycoplasma hypopneumoniae*, an antigen of *Actinobacillus pleuropneumoniae*, an antigen of *E. coli*, an antigen of Atrophic Rhinitis, an antigen of Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.

45. A vaccine of claim 43 wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.

46. A vaccine of claim 39 wherein the porcine circovirus type II antigen is an attenuated virus porcine circovirus type II.

47. A vaccine of claim 46 further comprising a veterinarily acceptable adjuvant.

48. A vaccine of claim 46 further comprising a freeze-drying stabilizer.

49. A vaccine of claim 39 wherein the porcine circovirus type II antigen is an inactivated porcine circovirus type II.

50. A vaccine of claim 49 further comprising a veterinarily acceptable adjuvant.

51. A vaccine according to claim 38 wherein the antigen of porcine circovirus comprises antigens of a plurality of porcine circoviruses.

52. A vaccine of claim 39 wherein the vaccine further comprises an additional antigen of another porcine pathogen.

53. A vaccine of claim 52 wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of *Mycoplasma hypopneumoniae*, an antigen of *Actinobacillus pleuropneumoniae*, an antigen of *E. coli*, an antigen of Atrophic Rhinitis, an antigen of Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.

54. A vaccine of claim 53 wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.

55. A vaccine of claim 39 wherein the porcine circovirus type II antigen comprises an antigen encoded by a porcine circovirus type II open reading frame (ORF) selected from the group consisting of ORFs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 13.

56. A vaccine of claim 39 wherein the porcine circovirus type II antigen comprises an antigen encoded by a porcine circovirus type II open reading frame (ORF) selected from the group consisting of ORFs 4, 7, 10, and 13.

57. A vaccine of claim 39 wherein the porcine circovirus type II antigen comprises a vector that contains and expresses *in vivo* an antigen encoded by a porcine circovirus type II open reading frame (ORF) selected from the group consisting of ORFs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 13.

58. A vaccine of claim 39 wherein the porcine circovirus type II antigen comprises a vector that contains and expresses *in vivo* an antigen encoded by a porcine circovirus type II open reading frame (ORF) selected from the group consisting of ORFs 4, 7, 10, and 13.

59. A vaccine of claim 57 wherein the vector is selected from the group consisting of a DNA plasmid, a linear DNA molecule, and a recombinant virus.

60. A vaccine of claim 58 wherein the vector is selected from the group consisting of a DNA plasmid, a linear DNA molecule, and a recombinant virus.

61. A vaccine of claim 59 wherein the recombinant virus is selected from the group consisting of pig herpes virus, porcine adenovirus, and poxvirus.

62. A vaccine of claim 60 wherein the recombinant virus is selected from the group consisting of pig herpes virus, porcine adenovirus, and poxvirus.

63. A vaccine of claim 61 wherein the recombinant virus is selected from the group consisting of Aujeszky's disease virus, vaccinia virus, avipox virus, canarypox virus, and swine pox virus.

64. A vaccine of claim 62 wherein the recombinant virus is selected from the group consisting of Aujeszky's disease virus, vaccinia virus, avipox virus, canarypox virus, and swine pox virus.

65. A method for inoculating against porcine parvovirus and porcine circovirus comprising administering to a porcine a vaccine as claimed in claim 38.